Latest Cytokine storm Stories
MONMOUTH JUNCTION, N.J., July 17, 2014 /PRNewswire/ -- CytoSorbents Corporation (OTCQB: CTSO), a critical care immunotherapy company commercializing its CytoSorb® cytokine adsorber in multiple
A protein called SOCS4 has been shown to act as a handbrake on the immune system's runaway reaction to flu infection, providing a possible means of minimizing the impact of flu pandemics.
Certain influenza strains are highly virulent—they cause more serious disease and kill more people.
Highly pathogenic (dangerous) influenza strains elicit a strong immune response which can lead to uncontrolled inflammation in the lung and potentially fatal lung injury.
MONMOUTH JUNCTION, N.J., March 13, 2014 /PRNewswire/ -- CytoSorbents Corporation (OTCQB: CTSO), a critical care immunotherapy company using blood purification to treat life-threatening illnesses in
A study led by St.
Many patients with hypertension are treated with ACE inhibitors.
- Withering but not falling off, as a blossom that persists on a twig after flowering.